Colloid vs Crystalloid: Crystalloids and Colloids in Fluid Resuscitation, Infusion, and Fluid Therapy

Fluid therapy plays an important role in maintaining circulation, tissue perfusion, and normal organ function. When a patient develops hypovolemia, dehydration, sepsis, shock, trauma, or significant blood loss, intravenous fluid may be administered to restore or support the circulating blood volume. However, effective fluid resuscitation involves more than simply replacing the amount of fluid that has been lost. The composition of the intravenous fluid, its distribution within the body’s fluid compartments, the amount administered, and the patient’s underlying condition all influence the response to treatment. Selecting an appropriate fluid therefore requires an understanding of how different solutions behave after administration and the potential benefits and complications associated with their use.

Crystalloids and colloids are the two major categories considered in intravenous fluid therapy. Crystalloid solutions contain water and relatively small dissolved particles that can move through semipermeable membranes and distribute primarily throughout the extracellular fluid compartment. Common examples include normal saline and balanced crystalloid solutions. Depending on their electrolyte composition and concentration, crystalloids can be classified as isotonic, hypotonic, or hypertonic, with each type producing different effects on fluid distribution and electrolyte balance. Their widespread availability, relatively low cost, and established role in fluid resuscitation have made crystalloids an important component of clinical practice.

Colloid solutions differ because they contain larger molecules that exert colloid osmotic pressure within the circulation. This property can promote retention of fluid in the intravascular space and produce intravascular volume expansion. Colloids include naturally occurring preparations such as albumin as well as synthetic products such as hydroxyethyl starch. Although the physiological behavior of colloids can make them useful in particular circumstances, their clinical use must be considered carefully because different colloid preparations have different safety profiles. The distinction between the colloid and crystalloid groups is therefore based not only on their composition but also on their effects on fluid movement, circulation, organ function, and clinical outcomes.

The question of Crystalloid Solution vs Colloid becomes especially relevant when fluid resuscitation is required. During resuscitation, the immediate objective is generally to improve effective circulating volume and tissue perfusion while avoiding unnecessary fluid administration. Crystalloids can provide substantial fluid replacement but distribute beyond the intravascular space, whereas colloids may produce more sustained intravascular expansion because of their larger molecules and oncotic effects. These differences can influence the volume of fluid required and the physiological response to treatment, but they do not mean that one category is universally superior. The appropriate choice depends on the clinical situation, the specific fluid preparation, and the potential risks and benefits for the individual patient.

Fluid selection is particularly important in critically ill patients because fluid administration often occurs alongside other interventions such as vasopressor therapy, blood transfusion, mechanical ventilation, and renal support. Patients with sepsis, shock, trauma, or major blood loss may require rapid assessment and carefully controlled administration of a resuscitation fluid. At the same time, excessive fluid administration can produce complications. Accumulation of excess crystalloid fluid may contribute to tissue and pulmonary edema, while some synthetic colloids have been associated with renal and coagulation complications. Significant blood loss may also require a blood product rather than continued administration of crystalloid or colloid alone because intravenous fluids do not replace the oxygen-carrying capacity of lost red blood cells.

An appropriate approach to fluid therapy therefore requires consideration of several interconnected factors:

1. The cause of fluid loss: Dehydration, hemorrhage, sepsis, burns, and other conditions produce different physiological disturbances and may require different treatment strategies.
2. The patient’s hemodynamic condition: Blood pressure, heart rate, peripheral perfusion, urine output, mental status, and other indicators help determine whether additional fluid may be beneficial.
3. The type and composition of the fluid: Electrolyte content, tonicity, buffering agents, and the presence or absence of large molecules can affect how the solution behaves after infusion.
4. The risks associated with administration: Fluid overload, electrolyte abnormalities, edema, renal complications, and coagulation disturbances must be considered alongside the potential benefit of volume expansion.
5. The patient’s response to treatment: Fluid therapy should be reassessed continuously rather than administered according to a fixed volume without considering the clinical response.

Understanding Crystalloid Solution vs Colloid therefore requires more than memorizing the names of individual fluids. It involves understanding how crystalloids and colloids differ in composition, distribution, intravascular volume expansion, duration of effect, clinical applications, and safety. It also requires recognizing that the choice of fluid is influenced by the patient’s condition and that fluid resuscitation is only one component of managing circulatory compromise.

This guide examines Crystalloid Solution vs Colloid by first exploring crystalloid solutions, including their major types and clinical uses, followed by the composition, types, and mechanism of colloid fluids. It then examines the physiological and clinical differences between the two groups, including fluid distribution, intravascular volume expansion, duration of action, and volume requirements. The discussion proceeds to the role of crystalloids and colloids in critically ill patients, with attention to evidence from fluid resuscitation studies and their use in conditions such as sepsis, shock, and major blood loss. Important complications, including renal and bleeding risks, fluid overload, electrolyte disturbances, and blood product considerations, are also addressed. Finally, the guide considers the practical factors that influence intravenous fluid selection, infusion, monitoring, reassessment, and safe nursing care.

Crystalloid Solution: Definition, Types, and Clinical Uses

A crystalloid solution is an intravenous fluid containing water and relatively small, water-soluble particles such as electrolytes and, in some formulations, glucose or other small molecules. Because these particles can move relatively freely across capillary membranes, crystalloid fluid distributes between the intravascular and interstitial spaces after administration. This distribution is important clinically because only a portion of an administered crystalloid remains within the circulation after equilibration. Consequently, the amount and composition of crystalloid administered must be considered in relation to the patient’s hemodynamic condition, ongoing losses, renal function, electrolyte status, and risk of fluid overload.

Crystalloids are among the most commonly used intravenous fluids for fluid resuscitation and other forms of fluid therapy. They can be used to restore circulating volume, replace extracellular fluid losses, correct selected electrolyte abnormalities, and provide maintenance fluid when an appropriate formulation is selected. Their clinical effects depend largely on their electrolyte concentration and tonicity. For practical purposes, crystalloid solutions are commonly grouped into isotonic, hypotonic, and hypertonic crystalloids.

The distinction is based on how the solution’s effective osmotic concentration compares with plasma and, consequently, how it influences the movement of water between body fluid compartments. Understanding this classification is essential because a crystalloid appropriate for rapid volume replacement may not be appropriate for routine maintenance or for correcting a specific sodium abnormality.

Isotonic, Hypotonic, and Hypertonic Crystalloid Solutions

The terms isotonic, hypotonic, and hypertonic describe the relationship between a crystalloid solution and plasma in terms of effective osmotic concentration. They help predict how administration of a particular fluid will affect the distribution of water throughout the body.

Isotonic Crystalloid Solutions

An isotonic crystalloid has an effective osmotic concentration that is broadly similar to plasma. When administered intravenously, it expands the extracellular compartment without causing a major immediate shift of water into or out of cells. This makes isotonic crystalloid solutions particularly important when the clinical objective is to increase extracellular and intravascular volume.

Common examples include:

• 0.9% sodium chloride (normal saline)
• Lactated Ringer’s solution
• Ringer’s solution
• Plasma-Lyte and other balanced crystalloid solutions

An isotonic crystalloid is frequently selected when a patient has intravascular volume depletion. For example, a patient who becomes hypotensive after significant gastrointestinal fluid losses may require an intravenous fluid bolus to restore circulating volume. Similarly, isotonic crystalloids are commonly used during the initial management of patients with sepsis or other forms of distributive shock.

However, isotonic does not mean that the fluid is identical to plasma. Different isotonic solutions have substantially different concentrations of sodium, chloride, potassium, calcium, magnesium, lactate, acetate, or other components. These differences can influence acid-base balance and electrolyte concentrations, particularly when relatively large volumes are administered.

NICE recommends using crystalloids containing sodium in the range of 130–154 mmol/L for adult intravenous fluid resuscitation and emphasizes that fluid prescriptions should specify the type, volume, and rate of administration.

Hypotonic Crystalloid Solutions

A hypotonic crystalloid has a lower effective osmotic concentration than plasma. After administration, water tends to move from the extracellular compartment toward the intracellular compartment, so hypotonic fluids are less effective for rapidly expanding the intravascular space.

Examples include:

• 0.45% sodium chloride, commonly called half-normal saline
• Some dextrose-containing solutions after glucose is metabolized

Because a hypotonic solution does not remain predominantly within the intravascular compartment, it is generally not the preferred crystalloid fluid for rapid fluid resuscitation. Merck Manual specifically notes that hypotonic fluids such as 0.45% saline and D5W should not be used for resuscitation because an even smaller proportion remains intravascularly.

Instead, hypotonic solutions may have roles in carefully selected situations involving free-water replacement or hypernatremia, depending on the patient’s overall fluid and electrolyte status. Their use requires careful monitoring because excessive administration can lower serum sodium and, when severe or rapidly developing, produce neurological complications.

For example, consider a patient with significant hypernatremia caused by inadequate free-water intake. Giving repeated boluses of isotonic saline may not address the underlying free-water deficit once intravascular stability has been achieved. A more hypotonic solution may be considered as part of a controlled correction strategy, with the rate and composition determined by the patient’s sodium level, volume status, renal function, and ongoing losses.

Hypertonic Crystalloid Solutions

A hypertonic crystalloid has a greater effective osmotic concentration than plasma. It draws water from the intracellular and interstitial compartments into the intravascular space, thereby increasing plasma volume while administering a relatively small volume of solution.

Examples include:

• 3% sodium chloride
• Higher-concentration hypertonic saline preparations used in specialized settings

Hypertonic crystalloid solutions have specific clinical applications rather than being routine choices for general volume replacement. One important application is the management of selected patients with severe symptomatic hyponatremia, where controlled administration of hypertonic saline can increase serum sodium and reduce cerebral edema. Hypertonic saline may also be used in selected neurological conditions to reduce intracranial pressure.

It is important to distinguish this specialized use from routine fluid resuscitation. Merck Manual notes that hypertonic saline is not generally recommended for resuscitation in critically ill patients but has a role in selected patients with neurologic injury to help reduce intracranial pressure.

Because hypertonic solutions can produce rapid changes in serum sodium and fluid distribution, administration requires close clinical and laboratory monitoring. Rapid correction of chronic hyponatremia, for example, can cause serious neurological injury. Thus, the concentration of a crystalloid fluid alone does not determine whether it is appropriate; the patient’s underlying physiological problem and the intended therapeutic objective are equally important.

Balanced Crystalloids vs Normal Saline

One of the most important clinical comparisons within the crystalloid group is balanced crystalloids versus normal saline. Both are commonly used isotonic fluids, but their electrolyte compositions are different.

Normal saline contains 0.9% sodium chloride, providing approximately 154 mmol/L of sodium and 154 mmol/L of chloride. This chloride concentration is substantially higher than the chloride concentration of normal plasma. When relatively large volumes are administered, saline can therefore increase serum chloride and contribute to hyperchloremic metabolic acidosis. NICE recommends monitoring serum chloride in patients receiving intravenous fluids with chloride concentrations above 120 mmol/L and reassessing the fluid prescription if hyperchloremia or acidemia develops.

Balanced crystalloids, such as Lactated Ringer’s solution and Plasma-Lyte, are formulated with electrolyte concentrations intended to more closely approximate the composition of extracellular fluid. They replace some of the chloride found in saline with other anions, such as lactate or acetate, and may also contain potassium, calcium, or magnesium depending on the preparation.

The difference can become clinically relevant when substantial volumes are administered. For example, a patient receiving several liters of 0.9% saline during resuscitation may develop a noticeable increase in serum chloride and a reduction in bicarbonate concentration. Balanced crystalloid solutions are designed to reduce this chloride load.

Clinical evidence comparing these fluids has produced important but nuanced findings. In the SMART trial, 15,802 critically ill adults were assigned to receive either saline or balanced crystalloids. The balanced-crystalloid group had a lower incidence of the composite outcome of death, new renal-replacement therapy, or persistent renal dysfunction: 14.3% compared with 15.4% in the saline group. The difference in 30-day in-hospital mortality alone was not statistically significant.

However, the evidence does not establish that balanced crystalloids are superior to saline for every patient or every clinical circumstance. The later PLUS trial, which included 5,037 critically ill adults, found no significant difference in 90-day mortality between Plasma-Lyte 148 and saline, and there was also no significant difference in new renal-replacement therapy.

These findings illustrate an important principle: fluid selection should be individualized rather than based on the assumption that one crystalloid is universally better than another. The patient’s diagnosis, electrolyte abnormalities, acid-base status, neurological condition, renal function, and anticipated volume of administration all matter.

For example:

• A patient requiring substantial-volume resuscitation may benefit from a balanced crystalloid to limit exposure to a high chloride load.
• A patient with certain neurological conditions may require careful consideration of sodium concentration and osmotic effects, and saline may be preferred in particular circumstances.
• A patient with hyperkalemia requires attention to the potassium content of balanced solutions.
• A patient with severe fluid overload may require a completely different strategy rather than continued administration of either crystalloid solution.

Thus, balanced crystalloids and normal saline should be viewed as different tools within the crystalloid group rather than interchangeable fluids with identical physiological effects.

Common Crystalloids Used for Fluid Resuscitation

Several crystalloids are used in clinical practice, but their purposes and compositions differ. The major examples include normal saline, Lactated Ringer’s solution, Plasma-Lyte, and hypertonic saline.

0.9% sodium chloride remains an extensively used crystalloid fluid. It provides sodium and chloride and can expand extracellular and intravascular volume. It may be selected for volume replacement, certain electrolyte disturbances, and situations in which a higher sodium or chloride concentration is specifically desirable. Its major limitation during large-volume administration is the potential for hyperchloremia and acid-base disturbances.

Lactated Ringer’s solution is a balanced crystalloid containing sodium, chloride, potassium, calcium, and lactate. The lactate is metabolized and contributes to bicarbonate generation under appropriate physiological conditions. It is widely used for volume replacement and resuscitation, including perioperative care, trauma, burns, and other settings involving extracellular fluid loss. It should nevertheless be selected with attention to the patient’s electrolyte and metabolic status.

Plasma-Lyte is another balanced crystalloid containing sodium, chloride, potassium, magnesium, and metabolizable buffer anions such as acetate and gluconate. Its electrolyte composition is designed to more closely resemble plasma than 0.9% saline. It has been extensively studied in critically ill patients, including in the SMART and PLUS trials.

Hypertonic saline, such as 3% sodium chloride, is a specialized crystalloid rather than a routine first-line resuscitation fluid. Its high sodium concentration creates an osmotic gradient that draws water into the intravascular compartment. It may be used in carefully selected neurological or severe hyponatremic conditions, with close monitoring of serum sodium and neurological status.

When a crystalloid is being considered for fluid resuscitation, the decision should be based on the clinical problem rather than simply on the availability of a particular bag of fluid. Important considerations include:

1. Reason for fluid administration: Resuscitation, maintenance, replacement of ongoing losses, and correction of specific electrolyte abnormalities are different indications.
2. Hemodynamic status: Hypotension, tachycardia, poor peripheral perfusion, altered mental status, and other findings may indicate a need for volume replacement, but they must be interpreted in the clinical context.
3. Electrolyte and acid-base status: Sodium, chloride, potassium, bicarbonate, and other laboratory findings can influence the choice of crystalloid.
4. Renal and cardiac function: Reduced ability to excrete water or electrolytes increases the risk of fluid accumulation.
5. Neurological status: The tonicity and sodium concentration of the fluid can be particularly important in patients with cerebral edema, traumatic brain injury, or significant sodium abnormalities.
6. Amount of fluid likely to be administered: The physiological consequences of the fluid’s composition become increasingly relevant as larger volumes are given.
7. Response to previous administration: Fluid therapy should be reassessed rather than continued automatically when the desired hemodynamic response has not occurred.

NICE emphasizes that intravenous fluid management should incorporate assessment, resuscitation, routine maintenance, replacement, redistribution, and reassessment rather than treating all IV fluid administration as the same clinical process.

For example, a patient with suspected hypovolemia and poor perfusion may receive an appropriate isotonic crystalloid bolus followed by reassessment of blood pressure, heart rate, capillary refill, urine output, respiratory status, and other indicators of response. If the patient improves, further fluid may not be necessary. If there is no improvement, simply administering increasingly large volumes of crystalloid may be inappropriate; the clinician must reconsider the cause of the instability, including ongoing blood loss, sepsis, cardiac dysfunction, obstructive shock, or another condition requiring a different intervention.

This distinction is central to safe crystalloid use. A crystalloid fluid is not merely a means of increasing the number on an intravenous fluid balance chart. Its composition, tonicity, dose, rate of infusion, and clinical indication determine whether its administration is likely to restore physiological stability or contribute to complications. In fluid resuscitation, the objective is therefore not to administer the greatest possible volume, but to provide an appropriate type of fluid in an appropriate amount while continuously evaluating the patient’s response.

Colloid Fluid: Definition, Types, and Mechanism

A colloid fluid is an intravenous fluid that contains relatively large molecules suspended or dissolved in a carrier solution. Unlike the small electrolytes found in most crystalloids, these larger molecules have a greater tendency to remain within the intravascular space and contribute to colloid osmotic pressure. This property can promote movement of water into the circulation and help maintain intravascular volume. The physiological effect, however, depends on the specific colloid solution, the size and characteristics of its molecules, the integrity of the capillary barrier, and the patient’s underlying condition.

The major types of colloids can be divided into natural and synthetic preparations. Albumin is the principal natural colloid used clinically, while synthetic colloids include hydroxyethyl starch, gelatin, and dextran preparations. These products are not interchangeable. Differences in molecular size, concentration, duration of intravascular retention, effects on coagulation, renal effects, and cost have important implications for clinical practice.

The theoretical advantage of colloid use is that larger molecules can exert an oncotic effect without requiring administration of as much fluid as might be necessary with a crystalloid to achieve a comparable initial expansion of the intravascular compartment. This concept is particularly relevant when considering patients who have already received substantial volumes of crystalloid. However, a larger molecule and greater oncotic effect do not automatically translate into improved clinical outcomes. Modern fluid therapy therefore considers both the desired physiological effect and the potential harms associated with individual colloid preparations.

Current critical-care guidance reflects this distinction. The 2026 Surviving Sepsis Campaign recommends crystalloids as the first-line fluid for resuscitation in adults with sepsis or septic shock. It suggests crystalloids alone rather than routine supplemental albumin, although albumin may be appropriate in selected patients who have already received large crystalloid volumes or have cirrhosis. The guideline recommends against starches for resuscitation.

Natural and Synthetic Colloids

Colloids can broadly be divided into natural colloids and synthetic colloids. This distinction is clinically important because the different products have substantially different safety profiles and indications.

Natural colloids are derived from substances that occur naturally in the body or from human plasma. The principal clinically relevant example is albumin. Albumin is a plasma protein synthesized primarily by the liver and is responsible for a large proportion of normal plasma oncotic pressure. Commercial albumin preparations are produced from human plasma and are available at different concentrations, most commonly 5% and 20–25% depending on the clinical application and formulation.

Albumin has several physiological functions beyond maintaining oncotic pressure. It contributes to the transport of various endogenous and exogenous substances, including hormones, fatty acids, bilirubin, and some medications. When administered intravenously, albumin can increase plasma oncotic pressure and influence the distribution of water between the intravascular and interstitial compartments.

The clinical role of albumin is more selective than simply treating it as a more powerful alternative to crystalloids. In sepsis, for example, current guidance recommends crystalloids as first-line resuscitation fluid and suggests crystalloids alone over routine addition of albumin. Supplemental albumin can be considered in selected adults who have already received large volumes of crystalloids or in certain patients with cirrhosis.

The synthetic colloid group includes several manufactured products:

• Hydroxyethyl starch (HES)
• Gelatin-based solutions
• Dextran solutions

These products were developed because their large molecules can remain within the vascular compartment and produce volume expansion. Historically, synthetic colloids were used extensively in perioperative and critical-care settings because clinicians hoped they would provide more efficient volume expansion than crystalloids.

However, evidence accumulated showing that the risks differ substantially among synthetic colloids. Hydroxyethyl starch has been associated with acute kidney injury, increased need for renal replacement therapy, bleeding concerns, and potentially increased mortality in critically ill populations. A systematic review and meta-analysis of randomized trials found that, after exclusion of retracted trials, HES was associated with increased mortality, renal failure, and use of renal replacement therapy compared with other resuscitation solutions.

For this reason, the term colloid should not be interpreted as meaning that every colloid solution has the same clinical value. Albumin, hydroxyethyl starch, gelatin, and dextran differ in composition, mechanism, pharmacokinetics, and adverse-effect profile.

For example, consider two patients who both require volume support. A patient with sepsis who has already received substantial crystalloid may be evaluated for whether albumin offers a useful additional option. A different patient with sepsis and evolving kidney injury would not be an appropriate candidate for hydroxyethyl starch simply because a colloid can produce intravascular volume expansion. The type of colloid matters as much as the general category.

Another important distinction is between colloid osmotic pressure and the actual clinical ability of a product to remain within the circulation. Theoretically, a larger molecule should exert a stronger oncotic effect, but capillary permeability changes substantially during inflammation, trauma, and critical illness. When the endothelial barrier becomes more permeable, colloid molecules may escape into the interstitial space, reducing their intended intravascular effect and potentially contributing to tissue edema.

Colloid Osmotic Pressure and Intravascular Fluid Retention

The primary physiological principle underlying colloid use is colloid osmotic pressure, also called oncotic pressure. This is the osmotic pressure generated by large molecules, particularly plasma proteins, that are relatively restricted from crossing the vascular barrier. In plasma, albumin is the major contributor.

To understand this concept, it helps to consider what happens after intravenous administration.

When a crystalloid solution is infused, its small dissolved particles can move relatively readily across capillary membranes. As a result, a substantial portion of the administered fluid eventually distributes into the extracellular interstitial space. A colloid, by contrast, contains larger molecules that normally cross the capillary wall less readily. These molecules exert an osmotic pull that favors retention of water within the vascular compartment.

A simplified example illustrates the principle. Suppose two patients receive intravenous solutions with the same initial volume. If one receives a crystalloid and the other receives a colloid, the colloid may produce greater initial intravascular volume expansion per unit of infused fluid because its larger molecules exert an oncotic effect. This does not mean that every colloid will always provide a superior clinical result. The effect depends on the patient’s vascular permeability, the specific product, the dose, and the underlying disease.

The relationship between colloid osmotic pressure and fluid movement can be understood through the forces governing movement of water across capillary walls. These include:

1. Hydrostatic pressure, which tends to push water out of the vascular space.
2. Colloid osmotic pressure, which tends to draw or retain water within the vascular compartment.
3. Capillary permeability, which determines how readily water and larger molecules can cross the vascular barrier.
4. Interstitial fluid pressure and protein concentration, which also influence movement between compartments.

In a healthy vascular system, albumin contributes substantially to plasma oncotic pressure. When albumin concentration falls substantially, the reduction in oncotic pressure can favor movement of water into the interstitial compartment. This is one reason hypoalbuminemia can be associated with edema, although edema formation is multifactorial and also depends on hydrostatic pressure, endothelial permeability, lymphatic drainage, and sodium and water balance.

The behavior of a colloid can change considerably in critically ill patients. Conditions such as sepsis and severe inflammation can alter endothelial integrity and increase capillary permeability. In such circumstances, the assumption that a colloid will remain confined to the intravascular space becomes less reliable. If large colloid molecules escape into the interstitial compartment, their oncotic effect may contribute to interstitial fluid retention rather than providing the desired sustained intravascular expansion.

This is an important reason why the physiological concept of colloid osmotic pressure should not be interpreted in isolation. A fluid may have a strong theoretical oncotic effect, yet the clinical benefit can be limited if the patient’s vascular barrier is severely disrupted.

Albumin illustrates this principle particularly well. Because albumin is a natural plasma protein, administering concentrated albumin can increase plasma oncotic pressure and expand intravascular volume. However, its clinical use must still be matched to the underlying condition. Current sepsis guidance does not recommend routine albumin in place of crystalloids for initial resuscitation; instead, it allows consideration of albumin in selected patients who have already received large crystalloid volumes or have cirrhosis.

The concentration of a colloid solution also matters. A 5% albumin solution has a different physiological effect from a 20% or 25% albumin preparation. More concentrated albumin solutions can exert a stronger oncotic effect and draw water into the intravascular space. Therefore, administration requires attention to the patient’s current fluid status and the possibility of intravascular volume overload.

The same principle helps explain why colloid administration should not be evaluated simply by asking whether the fluid “stays in the blood.” The clinically relevant questions include whether the patient is fluid responsive, whether increased intravascular volume improves perfusion, whether the vascular barrier is intact enough to retain the molecules, and whether the intervention produces more benefit than harm.

Hydroxyethyl Starch and Other Colloid Solutions

Hydroxyethyl starch is a synthetic colloid made by modifying starch molecules to produce a solution with volume-expanding properties. Different HES preparations have historically been described according to molecular weight, concentration, and degree of molar substitution. These characteristics influence how the molecules behave within the circulation and how quickly they are metabolized or eliminated.

Hydroxyethyl starch became widely used because it could produce substantial intravascular volume expansion while requiring less infused volume than might be needed with some crystalloid strategies. However, concerns about its safety became increasingly important as clinical trials evaluated outcomes in critically ill patients.

The major concerns surrounding HES include:

• Acute kidney injury
• Increased need for renal replacement therapy
• Coagulation abnormalities and bleeding
• Potential accumulation in tissues
• Potential increase in mortality in some critically ill populations

A major systematic review published in JAMA evaluated randomized trials involving critically ill patients receiving HES for acute volume resuscitation. After excluding trials affected by scientific misconduct concerns, HES was associated with increased mortality, renal failure, and renal replacement therapy compared with other resuscitation fluids. The investigators concluded that its use for acute volume resuscitation was not warranted because of serious safety concerns.

These findings have had a major influence on contemporary fluid practice. The Surviving Sepsis Campaign specifically recommends against starches for resuscitation in adults with sepsis or septic shock, with high certainty of evidence. It also suggests against gelatin for resuscitation.

The renal concern is particularly important. Hydroxyethyl starch can accumulate in the kidney and has been associated with kidney injury in critically ill populations. An increase in acute kidney injury is clinically significant because deterioration of renal function can lead to electrolyte disturbances, impaired fluid balance, accumulation of medications and metabolic waste products, and the eventual need for renal replacement therapy in severe cases. The concern is therefore not simply a laboratory abnormality; it can influence the entire course of critical illness.

Synthetic colloids can also interfere with coagulation. Some preparations may affect platelet function, coagulation factors, or clot formation, making their use particularly concerning when bleeding is already present or when a patient is at high risk of hemorrhage. This is especially relevant in trauma and major surgery, where maintaining effective hemostasis is essential.

Gelatin solutions are another type of synthetic colloid. They contain modified gelatin molecules and have been used as plasma-volume substitutes in some healthcare systems. Their ability to expand intravascular volume is accompanied by potential adverse reactions, including hypersensitivity and effects on coagulation. Current sepsis guidance suggests against gelatin for resuscitation.

Dextrans are polysaccharide-based colloids that can produce intravascular volume expansion. Their use has declined substantially because of concerns involving bleeding, renal effects, and hypersensitivity reactions. They are therefore not considered routine first-line fluids for modern critical-care resuscitation.

Albumin remains the most clinically important natural colloid. Unlike synthetic colloids, it is a naturally occurring human plasma protein and has a well-established physiological role in maintaining oncotic pressure. Nevertheless, albumin is not simply a universal replacement for crystalloids. The current evidence-based approach is selective use based on clinical circumstances rather than routine administration to every patient requiring volume resuscitation. In sepsis and septic shock, current guidance favors crystalloids initially, with albumin considered in selected circumstances such as after large crystalloid volumes or in some patients with cirrhosis.

The differences among the major colloid groups can therefore be summarized conceptually:

Colloid group	Main characteristic	Important clinical consideration
Albumin	Natural plasma protein with oncotic activity	Selective use; may be considered after large crystalloid volumes or in selected conditions
Hydroxyethyl starch	Synthetic starch-derived volume expander	Significant renal and safety concerns; not recommended for sepsis resuscitation
Gelatin	Synthetic protein-derived colloid	Limited role and potential adverse effects; not recommended for sepsis resuscitation
Dextran	Synthetic polysaccharide colloid	Limited modern use because of bleeding, renal, and hypersensitivity concerns

The key clinical principle is that colloid use should be based on the specific preparation rather than on the assumption that all colloids behave in the same way. The theoretical ability of a colloid to retain fluid intravascularly does not by itself establish a clinical advantage over crystalloids. In contemporary practice, the decision must incorporate the patient’s underlying disease, vascular permeability, renal function, bleeding risk, previous fluid administration, and evidence supporting the particular product.

For critically ill patients, this distinction is especially important. Modern guidelines place crystalloids at the center of initial resuscitation, while reserving albumin for selected situations and discouraging synthetic starches and other colloids with unfavorable safety profiles.

Crystalloid Versus Colloid: Physiological and Clinical Differences

The distinction between crystalloid versus colloid is based largely on how each type of fluid behaves after intravenous administration. Although both can increase circulating volume and support tissue perfusion, they differ in molecular composition, distribution across the vascular and interstitial compartments, intravascular persistence, and the amount of fluid required to achieve a desired hemodynamic response.

A crystalloid solution contains water and relatively small electrolytes or other small solutes that readily distribute throughout the extracellular fluid compartment. A colloid contains larger molecules, such as albumin or certain synthetic polymers, that can exert colloid osmotic pressure and may remain within the vascular space longer when the capillary barrier is relatively intact.

These physiological differences explain why crystalloid and colloid solutions have historically been viewed as having different volume-expanding properties. However, the practical difference should not be reduced to the idea that one fluid is always superior. Modern fluid therapy emphasizes the patient’s clinical condition, the reason for volume loss, the type of fluid, the amount administered, and the patient’s response.

Fluid Distribution and Intravascular Volume Expansion

After an intravenous fluid is administered, its ultimate distribution depends on its composition and the permeability of the vascular endothelium. This is one of the most important physiological distinctions when considering crystalloid versus colloid.

Crystalloids contain relatively small dissolved particles that can cross the capillary endothelium more readily than the larger molecules found in colloids. Consequently, an isotonic crystalloid does not remain entirely inside the blood vessels. A substantial proportion moves from the intravascular compartment into the interstitial space, while the water and electrolytes remain within the extracellular fluid compartment.

This means that a crystalloid infusion can increase blood volume and improve venous return, cardiac output, and tissue perfusion, but the intravascular effect may diminish as fluid redistributes. The process is especially important when large quantities of crystalloid are administered. Excessive administration can increase interstitial fluid and contribute to edema.

For example, a patient with acute hypovolemia may receive an isotonic crystalloid such as a balanced crystalloid solution. The immediate goal is not to permanently keep the entire infused volume inside the bloodstream. Rather, the goal is to provide enough fluid to increase effective circulating volume and improve perfusion while the underlying cause of the fluid loss is addressed.

Colloids behave differently because they contain larger molecules. Albumin, for example, contributes to plasma oncotic pressure and can help retain water within the vascular compartment. Synthetic colloids were developed partly because their larger molecular structures were expected to provide prolonged intravascular volume expansion.

This is the physiological basis for the traditional argument that colloids have larger volume-expanding effects than crystalloids. In an intact vascular barrier, a colloid molecule is less able to cross the capillary wall than the small electrolytes contained in a crystalloid. Consequently, colloid administration can produce relatively greater intravascular expansion per unit volume.

However, this effect is highly dependent on the patient’s condition. In critically ill patients, inflammation can increase endothelial permeability. When the vascular barrier becomes more permeable, even molecules that would normally be retained intravascularly can move into the interstitial space. Therefore, the theoretical advantage of a colloid may become less pronounced during severe systemic inflammation, sepsis, trauma, or other conditions associated with capillary leak.

The comparison can therefore be summarized as follows:

Feature	Crystalloid	Colloid
Main components	Water and small dissolved particles	Water containing larger molecules
Initial distribution	Mainly extracellular space	Greater intravascular retention when the vascular barrier is intact
Intravascular persistence	Generally shorter	Generally longer, depending on the colloid and clinical condition
Typical volume requirement	May require greater volume	May require less volume for similar hemodynamic targets
Edema potential	Increases with excessive administration	Not eliminated; can also contribute to edema, especially with capillary leak
Examples	0.9% saline, Lactated Ringer’s, Plasma-Lyte	Albumin, hydroxyethyl starch, gelatin, dextran
Current general role in resuscitation	Major first-line category	Selective use; depends on the specific colloid and clinical situation

Importantly, the frequently quoted idea that approximately three times as much crystalloid is needed compared with colloid should not be treated as a fixed clinical rule. Research has found substantial variation in the crystalloid-to-colloid volume ratio, with a systematic review estimating an overall ratio of about 1.5:1 and considerable heterogeneity between studies.

Duration of Action and Volume Requirements

The duration of intravascular effect is another important consideration in crystalloid versus colloid comparisons.

Because crystalloid particles distribute relatively readily within the extracellular compartment, the increase in intravascular volume produced by a crystalloid infusion may decline as fluid leaves the vascular space. This does not mean that the crystalloid has stopped having physiological effects. Instead, its distribution has changed. Some of the administered fluid remains in the intravascular compartment, while much of it becomes part of the interstitial extracellular fluid.

Consequently, achieving and maintaining a particular hemodynamic response may require repeated crystalloid administration. However, giving additional fluid should never be based simply on the amount already administered. The patient should be reassessed after a fluid challenge or bolus to determine whether additional fluid resuscitation is likely to improve circulation.

For example, consider a patient with vomiting, diarrhea, tachycardia, hypotension, and clinical evidence of volume depletion. An isotonic crystalloid may be administered and the patient’s blood pressure, heart rate, capillary refill, urine output, mental status, respiratory status, and other relevant indicators reassessed. If perfusion improves, additional fluid may not be necessary. If the patient remains unstable, the clinician must determine whether further fluid, a different intervention, treatment of the underlying cause, or vasopressor support is appropriate.

Colloids can remain intravascular for longer than many crystalloid solutions because their larger molecules exert oncotic effects and may be retained within the vascular space. Historically, this led to the concept that smaller quantities of colloid could produce an equivalent degree of intravascular expansion.

The distinction becomes particularly relevant when excessive fluid administration itself is a concern. A patient who requires substantial volume replacement may develop pulmonary or peripheral edema if large quantities of crystalloid are administered. In theory, a colloid could achieve a similar intravascular effect with a smaller infused volume.

However, volume requirements cannot be separated from fluid safety. A smaller infusion volume does not automatically mean a better clinical outcome. For example, hydroxyethyl starch may provide substantial volume expansion but has been associated with important adverse effects, including kidney injury and increased need for renal replacement therapy. Therefore, its volume-sparing property does not make it preferable to safer alternatives.

The duration of action also varies substantially within the colloid group. Albumin and synthetic colloids do not behave identically. Albumin is a naturally occurring plasma protein, whereas synthetic colloids such as hydroxyethyl starch have different molecular structures, metabolism, and elimination characteristics. Therefore, it is more accurate to discuss the behavior of a specific type of colloid rather than assuming that every colloid produces the same intravascular effect.

Another important consideration is the patient’s vascular integrity. In a patient with severe systemic inflammation and capillary leakage, a colloid may escape from the vascular compartment. Once a colloid moves into the interstitial space, its presence may contribute to interstitial fluid accumulation rather than providing the intended sustained intravascular expansion. This is one reason why physiological predictions about colloid vs crystalloid do not always translate directly into better clinical outcomes.

Modern evidence reinforces this point. The 2024 European Society of Intensive Care Medicine guideline conditionally favors crystalloids over albumin for volume expansion in critically ill adults generally and in patients with sepsis, although specific circumstances such as cirrhosis may alter the choice.

Advantages and Limitations of Crystalloids and Colloids

Both fluid categories have advantages and limitations, and the appropriate choice depends on the clinical purpose of the infusion.

Advantages of crystalloids

Crystalloids are widely available, relatively inexpensive, and familiar across a broad range of clinical settings. Their composition can be selected according to the patient’s physiological needs. For example, balanced crystalloids can provide sodium and other electrolytes with a composition designed to reduce the chloride load associated with large amounts of 0.9% saline.

Crystalloids are also versatile. An isotonic crystalloid can be used for many forms of volume replacement and fluid resuscitation, whereas specific hypotonic or hypertonic solutions may be selected for different indications. This flexibility makes the crystalloid group a major component of modern intravenous fluid therapy.

Their limitations primarily relate to distribution and the consequences of administering excessive amounts. Because crystalloid fluid distributes beyond the vascular compartment, repeated or large-volume administration can increase interstitial fluid and produce edema. This can be particularly problematic when the patient has impaired cardiac function, kidney dysfunction, increased vascular permeability, or established pulmonary edema.

The composition of the crystalloid also matters. Large amounts of chloride-rich 0.9% saline can contribute to hyperchloremia and metabolic acidosis, which is one reason balanced crystalloid solutions are often preferred when clinically appropriate. The 2024 ESICM guideline conditionally recommends balanced crystalloids over isotonic saline in critically ill patients generally and in patients with sepsis.

Advantages of colloids

The principal theoretical advantage of a colloid is its ability to increase intravascular volume with relatively greater vascular retention than a crystalloid under appropriate physiological conditions. Albumin can also contribute directly to plasma oncotic pressure.

This characteristic can make colloid administration attractive in situations where maintaining intravascular volume while limiting the volume of infused fluid is an important consideration. However, the clinical benefit depends on the particular colloid and the patient’s underlying condition.

Albumin is especially important because it is a natural colloid rather than a synthetic polymer. Its use may be considered in selected circumstances, although current evidence does not support routine substitution of albumin for crystalloids in most critically ill patients. The ESICM guideline recommends crystalloids rather than albumin for volume expansion in critically ill patients in general and in sepsis, while recognizing circumstances such as cirrhosis in which albumin may have a role.

Limitations of colloids

The main limitation is that greater intravascular persistence does not necessarily translate into better survival or fewer complications. The choice of colloid fluid therefore requires consideration of both its desired physiological effect and its safety profile.

Synthetic colloids illustrate this distinction particularly well. Hydroxyethyl starch can produce effective intravascular expansion, but concerns regarding renal injury and other adverse outcomes have substantially restricted its role. A major review of resuscitation fluids also found that semisynthetic colloids have safety concerns despite their greater intravascular persistence.

Cost and availability can also influence the choice. Albumin is generally more expensive than commonly used crystalloids, which can be particularly relevant when large-scale fluid resuscitation is required or resources are limited.

The most important clinical principle is therefore that crystalloids and colloids should not be selected solely according to how long they remain intravascularly. The fluid should be considered in relation to the patient’s hemodynamic state, cause of fluid loss, organ function, risk of fluid overload, and response to treatment.

For example, a patient with uncomplicated hypovolemia may respond appropriately to an isotonic crystalloid. Another patient with a specialized indication may be considered for albumin after careful assessment. A third patient may require a blood product rather than either crystalloid or colloid because the primary problem is substantial blood loss and loss of oxygen-carrying capacity. In that situation, replacing volume alone does not replace red blood cells or correct the underlying deficit.

Thus, when comparing colloids versus crystalloids, the practical question is not simply which fluid produces the greatest increase in intravascular volume. The more clinically useful question is which type of fluid can achieve the therapeutic objective with the lowest overall risk for that particular patient. Current critical-care guidance generally places crystalloids at the center of initial volume resuscitation, while reserving selected colloid solutions for specific circumstances rather than treating colloids as universally superior volume expanders.

Colloids Versus Crystalloids in Critically Ill Patients

Fluid selection becomes particularly important in critically ill patients because the physiological consequences of both inadequate and excessive fluid administration can be serious. A patient in shock may require rapid fluid resuscitation to restore effective circulating volume and tissue perfusion, but excessive administration can contribute to pulmonary edema, tissue edema, impaired gas exchange, and organ dysfunction.

The debate surrounding colloids versus crystalloids has therefore focused not only on which solution produces greater intravascular volume expansion, but also on whether that physiological difference translates into better survival, kidney outcomes, or other clinically meaningful benefits.

Current evidence has shifted substantially toward crystalloids as the routine resuscitation fluid for most critically ill adults. Colloids, particularly synthetic colloids such as hydroxyethyl starch, have a much more restricted role because their theoretical volume-expanding advantages have not consistently translated into improved patient outcomes and some have been associated with important harm. Current 2026 Surviving Sepsis Campaign guidance recommends crystalloids as the first-line fluid for adults with sepsis or septic shock and suggests balanced crystalloids rather than 0.9% saline for initial resuscitation.

Evidence From Fluid Resuscitation Studies

The comparison between crystalloid and colloid has been investigated in numerous randomized trials and systematic reviews. These studies have examined mortality, kidney injury, need for renal replacement therapy, hemodynamic response, and other outcomes.

One of the most influential studies was the SAFE trial, which compared 4% albumin with 0.9% saline in nearly 7,000 ICU patients requiring fluid resuscitation. The study found similar outcomes at 28 days between the two groups. This was important because albumin is a natural colloid solution, while saline is a crystalloid. The findings demonstrated that the theoretical ability of albumin to remain within the vascular space did not produce a general survival advantage over saline in an unselected ICU population.

The results also illustrate an important principle in crystalloid versus colloid research: a physiological difference does not automatically translate into a clinically important outcome difference. A fluid can produce a particular change in blood volume or oncotic pressure without necessarily reducing mortality or preventing organ dysfunction.

The CRISTAL trial examined colloids versus crystalloids in patients with hypovolemic shock. It found no significant difference in 28-day mortality, although a lower 90-day mortality was observed with colloids and required cautious interpretation. The investigators therefore did not establish a universal mortality advantage for colloid resuscitation.

The evidence becomes more concerning when synthetic colloids are considered. The 6S trial compared hydroxyethyl starch with Ringer’s acetate in patients with severe sepsis. Patients receiving hydroxyethyl starch had a higher risk of death at 90 days and were more likely to require renal replacement therapy.

Similarly, the CHEST trial compared 6% hydroxyethyl starch with saline in ICU patients. Although there was no significant difference in 90-day mortality, more patients receiving hydroxyethyl starch required renal replacement therapy.

These findings helped change the way colloid fluid is viewed in critical care. The question is no longer simply whether a colloid expands the intravascular compartment efficiently. The more important question is whether that expansion occurs without causing clinically important kidney, coagulation, or other complications.

Research has also examined the choice among different crystalloid solutions. The SMART trial included 15,802 critically ill adults and compared balanced crystalloids with saline. Major adverse kidney events within 30 days occurred in 14.3% of patients receiving balanced crystalloids compared with 15.4% receiving saline. Thirty-day in-hospital mortality was 10.3% versus 11.1%, respectively, although the mortality difference alone did not reach conventional statistical significance.

This evidence is relevant because crystalloids versus crystalloids is now an important part of fluid selection. The debate is not simply colloids and crystalloids. Clinicians must also consider whether a balanced crystalloid or 0.9% saline is most appropriate.

The 2024 European Society of Intensive Care Medicine guideline evaluated the evidence on resuscitation fluid selection in critically ill adults and provides recommendations addressing albumin versus crystalloids, balanced crystalloids versus saline, and hypertonic solutions.

Taken together, the evidence suggests several important points:

• Crystalloids remain the principal fluid resuscitation option for most critically ill patients.
• Albumin does not provide a universal mortality advantage over crystalloids.
• Synthetic colloids, particularly hydroxyethyl starch, have important safety concerns.
• Balanced crystalloids may have advantages over saline for some critically ill populations.
• Fluid choice should be individualized rather than based solely on the theoretical volume-expanding capacity of a solution.

Use in Sepsis, Shock, and Major Blood Loss

Sepsis and septic shock

Sepsis creates a particularly challenging environment for intravenous fluid therapy. Systemic inflammation can cause vasodilation, altered vascular permeability, and loss of effective circulating volume. The patient may therefore develop hypotension and impaired tissue perfusion even when total body water is not necessarily severely depleted.

For adults with sepsis or septic shock, current Surviving Sepsis Campaign guidance recommends crystalloids as the first-line fluid for resuscitation. The 2026 guideline also suggests balanced crystalloids over 0.9% saline during initial resuscitation.

This means that a balanced crystalloid such as Lactated Ringer’s or another balanced solution may be selected when there is a need for intravenous volume replacement. If balanced crystalloids are unavailable or inappropriate, 0.9% saline remains an accepted option.

The choice should not be interpreted as permission to administer unlimited fluid. Sepsis management increasingly emphasizes reassessment and avoidance of unnecessary fluid accumulation. A patient who remains hypotensive after an appropriate initial fluid challenge may require vasopressor therapy rather than repeated fluid boluses.

Albumin occupies a more selective position. Earlier Surviving Sepsis Campaign guidance suggested considering albumin in patients who had already received large volumes of crystalloids. The 2026 guidance is more conservative, recommending crystalloids alone over routine supplemental albumin while acknowledging circumstances in which albumin may be appropriate, such as selected patients who have received substantial crystalloid volumes or patients with cirrhosis.

Therefore, albumin and saline for fluid replacement should not be regarded as interchangeable treatments in every septic patient. The patient’s volume status, disease process, prior fluid administration, and risk of fluid accumulation all influence the decision.

Shock

Shock represents inadequate tissue perfusion and can arise from several mechanisms, including hypovolemia, distributive shock, cardiogenic shock, and obstructive shock. The role of crystalloid or colloid therefore depends partly on the cause of the shock.

In hypovolemic shock caused by fluid loss, an isotonic crystalloid may be appropriate for initial volume replacement. The response should then be assessed using clinical and hemodynamic indicators rather than assuming that a predetermined volume must be administered.

In distributive shock such as septic shock, crystalloids are generally used initially because the problem includes vasodilation and relative intravascular volume depletion. However, fluids alone do not correct the underlying vasoplegia. Vasopressors may become necessary when hypotension persists despite appropriate resuscitation.

In cardiogenic shock, indiscriminate fluid administration can be harmful because the heart may be unable to accommodate additional volume. In this setting, giving repeated crystalloid or colloid boluses simply because blood pressure is low may worsen pulmonary congestion. The underlying cardiac problem must be addressed.

This demonstrates why resuscitation in critically ill patients should be guided by the patient’s response rather than by a rigid crystalloid-to-colloid ratio.

Major blood loss

Major hemorrhage requires a different approach because the patient loses not only water and electrolytes but also red blood cells, coagulation factors, and platelets.

A crystalloid fluid can temporarily increase circulating volume, but it does not replace the oxygen-carrying capacity of a red blood cell or the hemostatic components of a blood product. Similarly, a colloid cannot substitute for blood when substantial hemorrhage has resulted in clinically significant loss of blood components.

For example, imagine a patient with severe traumatic blood loss who is hypotensive and tachycardic. Administering crystalloid may provide temporary volume support while hemorrhage control and blood-product resuscitation are initiated. However, progressively replacing large quantities of lost blood with crystalloid alone would dilute circulating red blood cells and coagulation factors.

The same principle applies to colloid administration. A colloid may expand plasma volume but does not restore the patient’s lost red blood cells or provide a complete replacement for the components of blood.

Therefore, blood loss changes the clinical question. Instead of asking only whether the patient needs a crystalloid or colloid, the team must determine whether the patient requires blood transfusion and a broader hemorrhage-control strategy.

Current Role of Crystalloids and Colloids in Critical Care

The modern role of crystalloids and colloids is best understood as selective rather than competitive. Crystalloids have become the foundation of initial volume resuscitation for most critically ill adults, while colloids are no longer routinely selected simply because they can produce greater intravascular volume expansion.

Current Surviving Sepsis Campaign recommendations strongly favor crystalloids as first-line resuscitation fluids in adults with sepsis or septic shock. Balanced crystalloids are suggested over 0.9% saline in the initial resuscitation of these patients.

The 2024 ESICM guideline similarly provides evidence-based recommendations for fluid selection in critically ill adults and generally favors crystalloids over albumin for volume expansion, while recognizing that specific clinical circumstances may warrant a different approach.

Albumin therefore retains a role, but it is a targeted role rather than routine replacement of crystalloids. Certain patients may benefit from albumin depending on the underlying disease and previous fluid exposure. For example, albumin has specific applications in selected patients with cirrhosis, and clinical guidelines may recommend it for particular complications of advanced liver disease.

Synthetic colloids have a substantially more restricted position. Hydroxyethyl starch is the clearest example. Although HES can expand intravascular volume, trials in severe sepsis and ICU populations raised significant concerns regarding mortality and kidney injury. Current sepsis guidance therefore recommends against starches for resuscitation.

The current approach can be summarized as follows:

Clinical situation	General fluid approach
Initial volume resuscitation in sepsis	Crystalloid, preferably balanced crystalloid when appropriate
Large-volume crystalloid exposure in selected patients	Consideration of albumin may be appropriate in specific circumstances
Routine resuscitation with hydroxyethyl starch	Generally avoided
Major hemorrhage	Blood products and hemorrhage control are central; crystalloid may have a limited supportive role
Cardiogenic shock	Avoid indiscriminate fluid loading; assess cardiac function and fluid responsiveness
Risk of fluid overload	Use smaller, reassessed fluid challenges and consider non-fluid interventions when appropriate
Traumatic brain injury	Fluid selection requires special consideration; current sepsis guidance favors 0.9% saline when sepsis coexists with TBI

The final point is especially important: fluid therapy is not simply about choosing between crystalloid versus colloid. The clinician must determine whether the patient needs fluid at all, whether the patient is likely to respond to fluid, which type of fluid is appropriate, how much should be administered, and when further administration should stop.

For example, a patient with septic shock and poor perfusion may initially receive a balanced crystalloid. If perfusion improves, additional fluid may not be required. If hypotension persists despite appropriate volume assessment, vasopressor therapy may be more appropriate than repeatedly administering intravenous fluid. Conversely, a patient with ongoing hemorrhage needs definitive bleeding control and appropriate blood-product replacement rather than progressively larger volumes of crystalloid.

This approach also explains why colloids versus crystalloids remains a clinically relevant distinction even though crystalloids are generally preferred. Understanding the physiological differences helps clinicians anticipate how a fluid will distribute, while understanding the evidence helps determine whether those theoretical advantages translate into better patient outcomes.

In current critical care, the goal is therefore not to maximize the intravascular volume expansion produced by an individual colloid solution or crystalloid solution. The goal is to restore adequate tissue perfusion while minimizing complications from both inadequate and excessive fluid administration. For most critically ill adults, that strategy places crystalloids—particularly balanced crystalloids—at the center of initial resuscitation, with albumin and other specialized fluids reserved for carefully selected circumstances.

Risks and Complications of Crystalloids and Colloids

Although intravenous fluids are essential in many clinical situations, neither crystalloids nor colloids are physiologically neutral. The same fluid that improves circulating volume and tissue perfusion can cause harm when the wrong type of fluid, excessive volume, or inappropriate infusion rate is used. The risks become particularly important in critically ill patients, who may have sepsis, acute kidney injury, cardiac dysfunction, endothelial injury, impaired coagulation, or other conditions that reduce their ability to tolerate additional fluid.

The complications associated with crystalloids and colloids differ according to their composition and physiological behavior. Crystalloids can contribute to fluid accumulation, edema, electrolyte abnormalities, and acid-base disturbances when administered in excessive amounts or when an inappropriate formulation is selected. Colloids can produce similar volume-related complications while also having additional risks that depend on the specific colloid solution.

Hydroxyethyl starch is an important example. Although it was developed to provide effective intravascular volume expansion, evidence has linked its use in certain critically ill and surgical populations with acute kidney injury, increased need for renal replacement therapy, bleeding, and mortality. The U.S. FDA added boxed warnings concerning mortality, kidney injury, and excess bleeding to HES products.

Renal and Bleeding Risks of Hydroxyethyl Starch

Hydroxyethyl starch (HES) is a synthetic colloid that was historically used for fluid resuscitation because its large molecules can produce substantial intravascular volume expansion. Different HES preparations vary in molecular weight, substitution characteristics, concentration, and carrier solution. Despite these differences, safety concerns have significantly reduced the role of HES in modern critical care.

The principal concerns are kidney injury, renal replacement therapy, bleeding, and mortality in particular patient populations.

Hydroxyethyl starch and kidney injury

The kidneys are particularly important when evaluating the safety of intravenous fluids because many fluid components and their metabolites must be handled by renal processes. Critically ill patients may already have reduced renal perfusion or evolving acute kidney injury, making them more vulnerable to additional renal stress.

Clinical studies have associated HES administration with increased risk of acute kidney injury and increased use of renal replacement therapy. The FDA’s review of randomized trials, meta-analyses, and observational data found evidence of increased mortality and acute kidney injury associated with HES in surgical patients, including increased need for renal replacement therapy. It also identified increased mortality and acute kidney injury in patients with blunt trauma.

The concern is particularly important because a patient requiring fluid resuscitation may already have several risk factors for kidney dysfunction. For example, a patient with septic shock may have hypotension, systemic inflammation, altered renal perfusion, and exposure to nephrotoxic medications. Adding a fluid associated with renal harm can make the overall clinical situation more complicated.

A simplified clinical example illustrates the issue:

A patient with severe sepsis develops hypotension and oliguria. An isotonic crystalloid is used for initial volume resuscitation, and the patient’s perfusion is reassessed. If HES were substituted simply because it provides greater intravascular volume expansion per unit volume, the theoretical volume advantage would need to be weighed against its potential renal toxicity. Current evidence and guidelines favor avoiding starches for resuscitation rather than accepting this risk for a presumed volume-sparing benefit.

The presence of acute kidney injury also changes how fluid administration should be approached. Reduced kidney function can decrease the patient’s ability to excrete sodium and water, increasing the likelihood that repeated intravenous fluid administration will produce positive fluid balance and edema.

Hydroxyethyl starch and bleeding

Bleeding is another major concern associated with HES. Synthetic colloids can interfere with hemostasis through effects on coagulation factors, platelet function, and dilution of circulating coagulation components. The degree of effect varies according to the specific product, dose, and clinical circumstances.

This becomes particularly concerning in patients who are already bleeding or who have undergone major surgery. A patient with trauma, gastrointestinal hemorrhage, or postoperative bleeding cannot be managed simply by increasing plasma volume. The underlying loss of red blood cells and coagulation components must also be addressed.

The FDA’s safety review specifically identified excess bleeding as an important risk associated with HES in surgical patients. Its labeling changes warn about mortality, kidney injury, and excess bleeding.

This illustrates an important distinction between a colloid fluid and a blood product. A colloid may expand plasma volume, but it does not replace the oxygen-carrying capacity of red blood cells or provide the full range of hemostatic components contained in blood products.

Because of these concerns, current Surviving Sepsis Campaign guidance recommends against starches for resuscitation in adults with sepsis or septic shock. The recommendation is based on high-certainty evidence.

Therefore, hydroxyethyl starch should not be viewed as simply another alternative in the routine choice between colloids and crystalloids. Its safety profile substantially limits its role in contemporary fluid therapy.

Fluid Overload, Edema, and Electrolyte Disturbances

Fluid overload is one of the most important complications of intravenous fluid administration. It can occur with either crystalloid or colloid fluid when the amount administered exceeds the patient’s ability to accommodate, distribute, or eliminate the fluid.

Fluid overload occurs when there is excessive accumulation of fluid in the body, often reflected by a persistently positive fluid balance, weight gain, peripheral edema, pulmonary edema, or worsening organ function.

The risk is especially important in patients with:

• Heart failure
• Acute or chronic kidney dysfunction
• Liver disease
• Sepsis
• Capillary leak
• Mechanical ventilation
• Reduced cardiac reserve
• Prolonged intensive care treatment

How crystalloid fluids can cause fluid overload

Because crystalloid solutions distribute throughout the extracellular compartment, large volumes can increase both intravascular and interstitial fluid. If administration continues after adequate circulating volume has been restored, additional fluid may no longer provide meaningful hemodynamic benefit.

For example, consider a patient who initially presents with severe hypovolemia and hypotension. An isotonic crystalloid improves blood pressure and peripheral perfusion. If additional fluid is repeatedly administered despite normalization of these indicators, the patient may develop peripheral edema or pulmonary congestion.

This is why fluid balance must be monitored rather than focusing only on the amount of fluid prescribed.

A patient may receive several liters of crystalloid fluid during the initial phase of treatment, but the clinical team must subsequently determine whether additional fluid is still needed. Current sepsis guidance specifically emphasizes frequent reassessment to avoid both under-resuscitation and over-resuscitation. After the acute resuscitation phase, active fluid removal may be considered when clinically appropriate, including diuretics or extracorporeal fluid removal in selected patients.

Pulmonary edema

Pulmonary edema is a particularly serious consequence of excessive fluid administration because excess fluid can interfere with pulmonary gas exchange.

A patient who receives excessive intravenous fluid may develop increasing oxygen requirements, crackles on auscultation, worsening respiratory distress, or radiographic evidence of pulmonary edema. The risk is particularly important in patients with left ventricular dysfunction or acute respiratory distress.

For example, if a patient with cardiogenic shock receives repeated crystalloid boluses despite poor cardiac pumping capacity, the additional fluid may increase pulmonary vascular pressures without producing an appropriate improvement in systemic perfusion.

This demonstrates why hypotension does not automatically mean that more fluid is required. The underlying cause of the hypotension and the patient’s likelihood of responding to additional fluid must be assessed.

Peripheral and tissue edema

Excess extracellular fluid can accumulate in dependent tissues, producing peripheral edema. In critically ill patients, generalized tissue edema can become extensive.

Edema can interfere with tissue oxygenation and wound healing and may complicate mobility, skin integrity, and vascular access. In severe cases, tissue swelling can contribute to impaired organ function.

Colloids are not exempt from this problem. Although colloid molecules may remain intravascularly longer than many crystalloid particles under normal conditions, patients with severe inflammation and increased capillary permeability may experience movement of colloid molecules into the interstitial space. Consequently, using a colloid does not guarantee protection against edema.

Electrolyte disturbances

Another major risk of crystalloid administration is electrolyte imbalance. Different crystalloid formulations contain different concentrations of sodium, chloride, potassium, calcium, lactate, acetate, or other components.

For example, large-volume administration of 0.9% saline can produce hyperchloremia. The resulting chloride load can contribute to metabolic acidosis and may influence renal physiology.

Balanced crystalloid solutions contain a more physiologically distributed electrolyte composition and generally have a lower chloride concentration than 0.9% saline. This is one reason current critical-care guidance often favors balanced crystalloids when appropriate. The 2026 Surviving Sepsis Campaign recommends balanced crystalloids over 0.9% saline for initial resuscitation in adults with sepsis or septic shock, while noting 0.9% saline as the preferred option in patients with sepsis and traumatic brain injury.

Electrolyte problems can also occur when a specialized fluid is administered without considering the patient’s existing laboratory values.

For instance, administering a sodium-containing solution to a patient who already has significant hypernatremia may worsen the sodium abnormality. Conversely, administering a hypotonic solution to a patient in whom hypotonic fluid is inappropriate can contribute to worsening hyponatremia.

Therefore, administration of fluids should be guided by both the clinical condition and laboratory findings when relevant.

Acid-base disturbances

The composition of the fluid can also affect acid-base balance. Large amounts of chloride-rich crystalloid can contribute to hyperchloremic metabolic acidosis. Balanced crystalloid solutions replace some of the chloride with other anions, such as lactate or acetate, which are metabolized or otherwise handled differently by the body.

This does not mean that balanced crystalloids are free of risks. They still contain substantial sodium and other electrolytes and can contribute to fluid overload when excessive quantities are administered.

The key principle is therefore that crystalloids contain different electrolyte compositions, and the choice between them should account for the patient’s existing electrolyte and acid-base status.

Preventing fluid-related complications

Safe fluid therapy involves repeated assessment rather than simply completing a prescribed volume. Important observations may include:

• Blood pressure and heart rate
• Respiratory rate and oxygen requirements
• Lung examination
• Peripheral edema
• Urine output
• Daily weight when appropriate
• Serum electrolytes
• Renal function
• Acid-base status
• Cumulative fluid balance
• Signs of improving or worsening tissue perfusion

For critically ill patients, the response to each fluid intervention is particularly important. If perfusion has improved and additional fluid no longer provides a meaningful benefit, continued administration may expose the patient to unnecessary risk.

Blood Product and Transfusion Considerations

One of the most important limitations of both crystalloid and colloid solutions is that they cannot replace every component lost during major hemorrhage.

A crystalloid can increase extracellular and intravascular volume, while a colloid can provide intravascular volume expansion through its larger molecules and oncotic properties. Neither, however, replaces the oxygen-carrying capacity of a red blood cell.

This distinction is critical when managing major blood loss.

Crystalloid and colloid are not substitutes for blood

Imagine a patient involved in a major motor vehicle collision who loses a large amount of blood. The patient may develop hypotension because circulating blood volume has fallen. Administering crystalloid can temporarily increase circulating volume, but the patient’s red blood cell mass remains reduced.

As hemorrhage continues, the patient may therefore require blood products to restore oxygen-carrying capacity and support hemostasis. Depending on the clinical circumstances, transfusion may involve red blood cells, plasma, platelets, or other components.

The same principle applies to colloid administration. A colloid can expand the plasma component of the circulation but does not restore lost red blood cells.

This is why blood product administration should be considered according to the type and severity of blood loss rather than treating colloid or crystalloid infusion as a complete replacement strategy.

Red blood cell transfusion

A red blood cell transfusion is intended primarily to increase oxygen-carrying capacity rather than simply increase fluid volume.

Current AABB international guidelines recommend a restrictive transfusion strategy for most hemodynamically stable hospitalized adults, with transfusion generally considered when hemoglobin is below 7 g/dL. Higher thresholds may be selected in certain populations, such as patients undergoing cardiac or orthopedic surgery or those with preexisting cardiovascular disease. Importantly, transfusion decisions should also incorporate the patient’s overall clinical context rather than relying on hemoglobin alone.

These thresholds should not be interpreted as applying mechanically to a patient with active massive hemorrhage. A patient who is actively losing blood may require urgent blood-product resuscitation before laboratory hemoglobin values fully reflect the extent of acute blood loss.

For example, a patient with rapidly ongoing hemorrhage and signs of shock should not be managed by waiting for a laboratory value to fall to a particular threshold before initiating appropriate emergency treatment.

Risks associated with transfusion

Although blood transfusion can be lifesaving, it also carries potential complications. These can include:

• Acute hemolytic transfusion reactions
• Febrile nonhemolytic reactions
• Allergic reactions
• Transfusion-associated circulatory overload
• Transfusion-related acute lung injury
• Electrolyte and metabolic abnormalities in particular circumstances
• Infectious risks, although modern screening substantially reduces transfusion-transmitted infections

Transfusion-associated circulatory overload is particularly relevant to the broader discussion of fluid overload. Blood products are themselves administered as fluid and can contribute to excessive intravascular volume, especially in patients with heart failure, kidney dysfunction, or limited cardiovascular reserve.

Therefore, switching from crystalloid administration to blood product administration does not eliminate the need to monitor volume status.

Fluid resuscitation and blood transfusion may occur together

In major hemorrhage, crystalloid and blood products are not necessarily mutually exclusive. A patient may initially require crystalloid while blood products are being prepared, while definitive hemorrhage control is pursued.

However, prolonged reliance on large volumes of crystalloid in severe hemorrhage can dilute red blood cells and coagulation components. Consequently, management of major bleeding requires attention to hemorrhage control and appropriate blood-component replacement rather than treating the problem solely as a deficit of circulating fluid.

This distinction is particularly important when comparing crystalloid versus colloid with blood products. Crystalloids and colloids are primarily volume-expanding fluids; blood products replace specific components of blood and therefore serve a fundamentally different purpose.

Albumin and blood products

Albumin deserves separate consideration because it is a natural colloid solution and is also a normal plasma protein. Albumin can increase oncotic pressure and contribute to intravascular volume expansion, but it should not be considered a substitute for red blood cells, plasma, or platelets when those components have been lost.

Current 2026 Surviving Sepsis Campaign guidance recommends crystalloids alone over routine addition of albumin for fluid resuscitation in adults with sepsis or septic shock. Supplemental albumin may be appropriate in selected circumstances, including some patients who have already received large crystalloid volumes or patients with cirrhosis; the guideline advises avoiding supplemental albumin in patients with traumatic brain injury.

Nursing considerations during fluid and transfusion therapy

Safe fluid therapy requires continuous assessment. The nurse should monitor the patient’s response to the prescribed iv fluid, recognize evidence of fluid overload or inadequate perfusion, and promptly communicate clinically significant changes.

When a patient is receiving crystalloid or colloid infusion, relevant observations include:

• Vital signs and trends
• Respiratory status and oxygen saturation
• Lung sounds
• Urine output
• Peripheral and dependent edema
• Level of consciousness
• Skin perfusion and capillary refill
• Intake and output
• Cumulative fluid balance
• Serum electrolytes and renal function when ordered
• Signs of an adverse reaction

When a blood transfusion is prescribed, additional attention is required for patient identification, compatibility checks, baseline assessment, monitoring during administration, and recognition of transfusion reactions according to institutional protocol.

A useful clinical example is a patient with septic shock who initially receives crystalloid resuscitation. If blood pressure and perfusion improve, continued fluid administration should be reassessed rather than automatically continued. If the patient subsequently develops increasing oxygen requirements, pulmonary crackles, worsening edema, and a markedly positive fluid balance, the healthcare team must consider fluid overload rather than interpreting the findings as evidence that more fluid is needed.

The 2026 Surviving Sepsis Campaign specifically emphasizes frequent reassessment during fluid resuscitation and recommends consideration of active fluid removal after the acute resuscitation phase when clinically appropriate.

The central principle is therefore appropriate fluid for the appropriate indication, with repeated reassessment. Crystalloids remain the principal resuscitation fluids for many critically ill patients, while colloids have more selective indications. Hydroxyethyl starch is particularly restricted because of its renal, bleeding, and mortality concerns. Meanwhile, major hemorrhage requires recognition that neither crystalloid nor colloid can replace the oxygen-carrying and hemostatic functions of appropriate blood products.

Choosing an Intravenous Fluid in Clinical Practice

Choosing an intravenous fluid is a clinical decision rather than a simple choice between crystalloid versus colloid. The appropriate fluid depends on why the patient needs fluid, what has been lost, the patient’s cardiovascular and renal function, electrolyte and acid-base status, and how the patient responds to the initial infusion.

A useful framework is to distinguish five purposes of fluid therapy: resuscitation, routine maintenance, replacement of abnormal losses, redistribution of fluid, and reassessment. NICE specifically recommends considering these five principles—the “5 Rs”—when prescribing IV fluids.

For fluid resuscitation, the immediate objective is to restore adequate circulation and tissue perfusion without causing unnecessary fluid accumulation. For maintenance therapy, the objective is different: the patient needs enough water and electrolytes to meet normal physiological requirements when oral or enteral intake is inadequate. A patient losing fluid through vomiting, diarrhea, drains, burns, or other processes may require a replacement strategy that reflects the composition of those losses.

Consequently, there is no single “best” type of fluid for every patient. Even among crystalloids, the choice may be between a balanced crystalloid, 0.9% saline, or another formulation. Colloids, particularly albumin, may have selective applications, while synthetic colloids such as hydroxyethyl starch have a very limited role because of their safety concerns.

Factors Influencing Resuscitation Fluid Selection

The first question should be whether the patient actually needs fluid resuscitation. Hypotension alone does not establish that additional fluid is appropriate. A low blood pressure may result from hypovolemia, vasodilation, cardiac dysfunction, obstruction, or other causes that require different treatments.

Assessment should therefore combine the patient’s history, physical examination, laboratory findings, and clinical trends. Useful indicators include blood pressure, heart rate, capillary refill, peripheral temperature, urine output, mental status, respiratory status, and evidence of pulmonary or peripheral edema. NICE also identifies passive leg raising as a bedside method that can help assess fluid responsiveness in appropriate patients.

The underlying cause of the volume deficit is particularly important.

For example:

• A patient with uncomplicated dehydration from gastrointestinal losses may require an isotonic crystalloid for volume replacement.
• A patient with septic shock may require crystalloid resuscitation together with treatment of infection and, if hypotension persists, vasopressor support.
• A patient with major hemorrhage requires consideration of blood product replacement rather than relying on crystalloid alone.
• A patient with cardiogenic shock may deteriorate with excessive fluid because the failing heart cannot effectively accommodate additional volume.
• A patient with severe kidney dysfunction may be particularly vulnerable to fluid accumulation.
• A patient with significant electrolyte abnormalities may require a fluid whose composition does not worsen the existing disturbance.

The current 2026 Surviving Sepsis Campaign recommends crystalloids as the first-line fluid for adults with sepsis or septic shock. For initial resuscitation, balanced crystalloids are suggested over 0.9% saline, although 0.9% saline is suggested when sepsis occurs with traumatic brain injury. The guideline also recommends against starches and suggests against gelatin for resuscitation.

Balanced crystalloids versus saline

The choice within the crystalloid group also matters. Balanced crystalloid solutions contain electrolytes in proportions designed to reduce the chloride load compared with 0.9% saline. Lactated Ringer’s and other balanced solutions are common examples.

0.9% saline remains an important resuscitation fluid, but large-volume administration can produce hyperchloremia and acid-base disturbances. NICE recommends monitoring serum chloride in patients receiving IV fluids containing more than 120 mmol/L of chloride, such as 0.9% saline, and reassessing the prescription if hyperchloremia or acidemia develops.

This does not mean that balanced crystalloids are appropriate for every clinical situation. Fluid selection should account for the patient’s electrolyte abnormalities, neurological condition, renal function, acid-base status, and other circumstances.

For example, the 2026 sepsis guideline specifically recommends 0.9% saline rather than balanced crystalloid in patients with sepsis and traumatic brain injury.

Crystalloids versus colloids

The choice between colloid and crystalloid should also consider safety, not merely intravascular volume expansion.

Albumin is the principal natural colloid used clinically. Current sepsis guidance favors crystalloids alone over routine supplemental albumin but recognizes that albumin may be appropriate in selected patients who have already received large crystalloid volumes or who have cirrhosis.

Synthetic colloids require much greater caution. Hydroxyethyl starch, for example, is not simply an alternative to a balanced crystalloid. Its association with kidney injury and other adverse outcomes has substantially restricted its use, and current sepsis guidance recommends against starches for resuscitation.

Patient-specific factors

The same fluid can be appropriate for one patient and inappropriate for another. Important factors include:

• Cardiac function: heart failure can make excessive volume particularly dangerous.
• Renal function: impaired renal excretion increases the risk of fluid accumulation.
• Liver disease: cirrhosis and hypoalbuminemia may influence the choice of fluid in selected situations.
• Neurological status: patients with traumatic brain injury may require different fluid considerations.
• Electrolytes: existing sodium, chloride, potassium, and acid-base abnormalities influence fluid selection.
• Cause and severity of fluid loss: gastrointestinal losses, hemorrhage, burns, sepsis, and third-spacing do not have identical fluid requirements.
• Current fluid balance: previous IV fluids, oral intake, enteral nutrition, medications, and blood products all contribute to total fluid exposure.
• Response to previous fluid: improvement after a bolus supports the possibility that additional fluid may be beneficial; deterioration or absence of meaningful response should prompt reassessment.

NICE emphasizes that prescriptions should account for all sources of fluid and electrolyte intake, including oral or enteral intake, medications, IV nutrition, blood, and blood products.

Infusion, Monitoring, and Fluid Reassessment

The first question should be whether the patient actually needs fluid resuscitation. Hypotension alone does not establish that additional fluid is appropriate. A low blood pressure may result from hypovolemia, vasodilation, cardiac dysfunction, obstruction, or other causes that require different treatments.

Assessment should therefore combine the patient’s history, physical examination, laboratory findings, and clinical trends. Useful indicators include blood pressure, heart rate, capillary refill, peripheral temperature, urine output, mental status, respiratory status, and evidence of pulmonary or peripheral edema. NICE also identifies passive leg raising as a bedside method that can help assess fluid responsiveness in appropriate patients.

The underlying cause of the volume deficit is particularly important.

For example:

• A patient with uncomplicated dehydration from gastrointestinal losses may require an isotonic crystalloid for volume replacement.
• A patient with septic shock may require crystalloid resuscitation together with treatment of infection and, if hypotension persists, vasopressor support.
• A patient with major hemorrhage requires consideration of blood product replacement rather than relying on crystalloid alone.
• A patient with cardiogenic shock may deteriorate with excessive fluid because the failing heart cannot effectively accommodate additional volume.
• A patient with severe kidney dysfunction may be particularly vulnerable to fluid accumulation.
• A patient with significant electrolyte abnormalities may require a fluid whose composition does not worsen the existing disturbance.

The current 2026 Surviving Sepsis Campaign recommends crystalloids as the first-line fluid for adults with sepsis or septic shock. For initial resuscitation, balanced crystalloids are suggested over 0.9% saline, although 0.9% saline is suggested when sepsis occurs with traumatic brain injury. The guideline also recommends against starches and suggests against gelatin for resuscitation.

Balanced crystalloids versus saline

The choice within the crystalloid group also matters. Balanced crystalloid solutions contain electrolytes in proportions designed to reduce the chloride load compared with 0.9% saline. Lactated Ringer’s and other balanced solutions are common examples.

0.9% saline remains an important resuscitation fluid, but large-volume administration can produce hyperchloremia and acid-base disturbances. NICE recommends monitoring serum chloride in patients receiving IV fluids containing more than 120 mmol/L of chloride, such as 0.9% saline, and reassessing the prescription if hyperchloremia or acidemia develops.

This does not mean that balanced crystalloids are appropriate for every clinical situation. Fluid selection should account for the patient’s electrolyte abnormalities, neurological condition, renal function, acid-base status, and other circumstances.

For example, the 2026 sepsis guideline specifically recommends 0.9% saline rather than balanced crystalloid in patients with sepsis and traumatic brain injury.

Crystalloids versus colloids

The choice between colloid and crystalloid should also consider safety, not merely intravascular volume expansion.

Albumin is the principal natural colloid used clinically. Current sepsis guidance favors crystalloids alone over routine supplemental albumin but recognizes that albumin may be appropriate in selected patients who have already received large crystalloid volumes or who have cirrhosis.

Synthetic colloids require much greater caution. Hydroxyethyl starch, for example, is not simply an alternative to a balanced crystalloid. Its association with kidney injury and other adverse outcomes has substantially restricted its use, and current sepsis guidance recommends against starches for resuscitation.

Patient-specific factors

The same fluid can be appropriate for one patient and inappropriate for another. Important factors include:

• Cardiac function: heart failure can make excessive volume particularly dangerous.
• Renal function: impaired renal excretion increases the risk of fluid accumulation.
• Liver disease: cirrhosis and hypoalbuminemia may influence the choice of fluid in selected situations.
• Neurological status: patients with traumatic brain injury may require different fluid considerations.
• Electrolytes: existing sodium, chloride, potassium, and acid-base abnormalities influence fluid selection.
• Cause and severity of fluid loss: gastrointestinal losses, hemorrhage, burns, sepsis, and third-spacing do not have identical fluid requirements.
• Current fluid balance: previous IV fluids, oral intake, enteral nutrition, medications, and blood products all contribute to total fluid exposure.
• Response to previous fluid: improvement after a bolus supports the possibility that additional fluid may be beneficial; deterioration or absence of meaningful response should prompt reassessment.

NICE emphasizes that prescriptions should account for all sources of fluid and electrolyte intake, including oral or enteral intake, medications, IV nutrition, blood, and blood products.

Nursing Considerations for Safe Fluid Therapy

Nursing care is central to safe IV fluid administration because nurses frequently administer the infusion, monitor the patient continuously, identify changes in clinical status, document intake and output, and communicate deterioration to the healthcare team.

Safe nursing management begins before the fluid is connected.

Verify the prescription and the patient

Before starting an intravenous fluid, verify:

• Correct patient
• Correct type of fluid
• Correct concentration
• Correct route
• Correct volume
• Correct infusion rate
• Appropriate IV access
• Expiration and integrity of the fluid container
• Relevant allergies or contraindications
• Compatibility with concurrently administered medications

The nurse should also determine why the fluid was prescribed. A bag of crystalloid intended for rapid resuscitation should not be treated in the same way as a maintenance fluid intended to run slowly over many hours.

NICE emphasizes that IV fluids should be prescribed and administered by appropriately skilled healthcare professionals and that the prescription should clearly identify the type, rate, and volume.

Assess the patient before and during infusion

Baseline assessment provides a point of comparison for determining whether the infusion is producing the intended effect.

Assessment may include:

• Blood pressure
• Heart rate
• Respiratory rate
• Oxygen saturation
• Temperature
• Mental status
• Capillary refill
• Peripheral temperature
• Lung sounds
• Peripheral edema
• Jugular venous pressure when clinically appropriate
• Urine output
• Existing fluid balance
• Recent laboratory results

During administration, the nurse should watch for both therapeutic response and adverse effects.

For example, if a patient receiving crystalloid for hypovolemia develops improved blood pressure and peripheral perfusion without respiratory deterioration, the treatment may be achieving its intended objective. If the same patient develops new crackles, increasing dyspnea, and declining oxygen saturation, the nurse should recognize possible fluid intolerance and promptly communicate the change.

Monitor the IV site

The IV access itself requires regular assessment. Depending on the type of access and institutional policy, the nurse should monitor for:

• Pain
• Redness
• Swelling
• Leakage
• Coolness around the insertion site
• Resistance to infusion
• Signs of phlebitis
• Infiltration or extravasation where relevant
• Local infection

An infusion that is technically running does not necessarily mean that fluid is being delivered safely into the intended vascular compartment.

Maintain accurate intake and output

Accurate intake and output measurement is one of the most important aspects of fluid balance assessment.

The total intake should account for more than the primary IV bag. It may include:

• Maintenance IV fluids
• Fluid boluses
• Medication diluents
• Blood products
• Enteral feeds and free water
• Oral intake when applicable
• Other prescribed infusions

Output may include:

• Urine
• Vomiting
• Diarrhea
• Surgical drains
• Nasogastric drainage
• Other measurable losses

NICE specifically recommends accounting for all sources of fluid and electrolyte intake and maintaining fluid balance monitoring during IV fluid therapy.

This becomes especially important when several infusions are running simultaneously. A patient may receive a seemingly modest amount from each individual source but accumulate a substantial total volume over 24 hours.

Recognize fluid overload early

A nurse should recognize early signs that the patient may no longer tolerate additional fluid. These can include increasing peripheral edema, rising respiratory rate, new crackles, worsening oxygen requirements, increasing weight, and deteriorating respiratory status.

For example, consider an older patient with reduced cardiac and renal reserve who receives IV crystalloid for poor oral intake. If the patient’s blood pressure improves but the patient subsequently develops increasing dyspnea and bilateral crackles, the priority is not simply to continue the maintenance fluid because it was originally prescribed. The patient requires reassessment of the indication, current fluid status, and overall treatment plan.

Monitor for inadequate resuscitation

The opposite problem is failure to provide sufficient resuscitation fluid when true hypovolemia is present. Signs may include persistent hypotension, tachycardia, delayed capillary refill, cold extremities, altered mental status, oliguria, and other evidence of poor tissue perfusion.

The nurse should communicate persistent abnormalities rather than assuming that the prescribed fluid volume will automatically correct the problem.

In sepsis, for example, persistent hypotension after appropriate crystalloid administration may indicate the need for vasopressor therapy rather than an instruction to continue giving increasingly large amounts of fluid. The current Surviving Sepsis Campaign specifically supports vasopressor initiation when hypotension persists after initial crystalloid resuscitation.

Special considerations for colloids

When a colloid solution is prescribed, nursing monitoring remains similar in principle but should also reflect the specific risks associated with that product.

Albumin, for example, can expand intravascular volume and should be administered with attention to the patient’s cardiovascular and pulmonary status. Synthetic colloids such as hydroxyethyl starch require particular caution because of their safety profile and restricted clinical role.

A nurse should therefore understand that “colloid” is not a single homogeneous fluid category. Different types of colloids have different compositions, indications, and risks.

Special considerations for blood products

When fluid administration involves a blood product, additional safety procedures apply. Patient identification, compatibility verification, baseline assessment, appropriate monitoring, and recognition of transfusion reactions are essential.

Blood products also contribute to total fluid exposure. Therefore, a patient receiving red blood cells, plasma, platelets, crystalloid, and medication infusions may accumulate a substantial amount of fluid even though no single infusion appears excessive.

For hemodynamically stable adults, transfusion decisions should be based on hemoglobin together with the overall clinical context rather than an isolated laboratory number. The 2023 AABB international guideline recommends considering transfusion at a hemoglobin concentration below 7 g/dL for most hospitalized, hemodynamically stable adults, with different thresholds potentially appropriate for selected surgical or cardiovascular populations.

This threshold does not replace clinical judgment in active hemorrhage, where ongoing blood loss and hemodynamic instability require a different approach.

Patient education and documentation

Patients receiving IV fluids should understand, where appropriate, why the infusion is being given and what symptoms should be reported. NICE recommends involving patients in fluid management and explaining signs and symptoms that may indicate a need to adjust therapy.

Documentation should accurately record the type and amount of fluid administered, infusion rate, relevant assessments, intake and output, patient response, and any complications or interventions.

A complete record allows the healthcare team to determine whether the patient is receiving an appropriate amount of fluid rather than repeatedly making decisions without knowing the cumulative exposure.

Putting the Decision Into Practice

A practical approach to choosing an intravenous fluid can be summarized as:

1. Identify the purpose. Determine whether the patient needs resuscitation, maintenance, replacement, or another form of fluid therapy.
2. Assess the patient. Evaluate circulation, respiratory status, renal function, electrolytes, fluid balance, and the underlying cause of the problem.
3. Select the appropriate fluid. Consider the difference between a balanced crystalloid, saline, albumin, another specialized fluid, or a blood product.
4. Determine the volume and rate. Avoid treating fluid prescriptions as fixed quantities that should continue regardless of patient response.
5. Administer safely. Verify the prescription, IV access, fluid, concentration, and infusion rate.
6. Reassess. Look for improved perfusion as well as evidence of fluid intolerance.
7. Stop, modify, or escalate treatment when necessary. Persistent shock may require vasopressors or another intervention rather than additional fluid.
8. Continue monitoring. Follow fluid balance, renal function, electrolytes, respiratory status, and other clinically relevant indicators.

For example, a patient with septic shock may receive an initial balanced crystalloid fluid bolus. The healthcare team then evaluates blood pressure, capillary refill, mental status, urine output, lactate trends, respiratory status, and other measures of perfusion. If the patient remains hypotensive but shows evidence that additional fluid is unlikely to help, vasopressor therapy may become more appropriate. Current guidelines emphasize dynamic assessment and individualized fluid administration rather than indiscriminate continuation of fluids.

The central principle in crystalloid versus colloid selection is therefore not simply which fluid produces the greatest intravascular expansion. Safe fluid therapy requires matching the fluid to the patient’s physiological problem, administering an appropriate amount at an appropriate rate, and repeatedly reassessing whether the intervention is helping or causing harm. This approach allows crystalloids, colloids, blood products, and other therapies to be used according to their distinct clinical purposes rather than treating them as interchangeable forms of volume replacement.

Conclusion

Understanding Crystalloid Solution vs Colloid requires more than comparing how much fluid remains within the intravascular space. Crystalloids and colloids differ in composition, distribution, oncotic effects, duration of intravascular expansion, and potential complications, making fluid selection an important part of safe and effective fluid therapy. Crystalloids, particularly balanced crystalloid solutions, remain the foundation of fluid resuscitation for most critically ill patients because they are widely available, versatile, and supported by substantial clinical evidence.

Colloids, especially albumin, have more selective applications. Their ability to influence colloid osmotic pressure can be useful in specific clinical circumstances, but greater intravascular volume expansion does not necessarily produce better patient outcomes. Synthetic colloids such as hydroxyethyl starch have a much more limited role because of concerns involving kidney injury, renal replacement therapy, bleeding, and mortality.

The distinction between crystalloids and colloids is also important when managing sepsis, shock, dehydration, and major blood loss. Neither fluid category should be viewed as a substitute for a blood product when red blood cells or coagulation components have been lost. Similarly, administering additional fluid is not always the appropriate response to persistent hypotension. The patient’s underlying condition, fluid responsiveness, cardiovascular function, renal status, electrolyte balance, and cumulative fluid balance must all be considered.

Ultimately, effective fluid therapy depends on choosing the appropriate type of fluid, administering it at an appropriate volume and rate, and continually reassessing the patient’s response. A well-chosen crystalloid solution, carefully selected colloid, or appropriate blood product can support circulation and tissue perfusion when used for the right indication. At the same time, careful monitoring is essential to prevent fluid overload, edema, electrolyte disturbances, renal complications, and other adverse effects. The goal of Crystalloid Solution vs Colloid decision-making is therefore not simply to expand blood volume, but to restore adequate perfusion while minimizing avoidable harm.

Frequently Asked Questions

What are examples of crystalloids?
Common examples of crystalloids include 0.9% normal saline, Lactated Ringer’s solution, Ringer’s solution, Plasma-Lyte, 0.45% saline, and 3% hypertonic saline.

Is dextrose a colloid or crystalloid?
Dextrose is a crystalloid. Solutions such as D5W contain small, dissolved molecules that can cross capillary membranes and distribute throughout body water.

What is the difference between crystalloid and colloid solutions?
Crystalloid solutions contain small dissolved particles, such as electrolytes or glucose, and distribute between the intravascular and interstitial spaces. Colloid solutions contain larger molecules, such as albumin or synthetic starches, that exert colloid osmotic pressure and can remain in the intravascular space longer when the capillary barrier is intact.

What are 5 examples of colloids?
Five examples of colloids are albumin, hydroxyethyl starch (HES), gelatin solutions, dextran, and plasma. Albumin is a natural colloid, while HES, gelatin, and dextran are synthetic colloids. Plasma is a blood product containing proteins and other components.